Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: Recurrent event analysis

Haematologica

Volumn 100, Issue 6, 2015, Pages 740-747

  Stanworth, Simon J ^a,b   Hudson, Cara L ^c,d   Estcourt, Lise J ^a,b   Johnson, Rachel J ^c,d   Wood, Erica M ^e  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BINOMIAL REGRESSION; BLEEDING; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; FEVER; FOLLOW UP; GENDER; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL CONCEPTS; TEMPERATURE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING; CONTROLLED STUDY; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TRENDS;

FEMALE; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 84930532502     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118075     Document Type: Article

References (23)

1. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. New Engl J Med. 2010;362(7):600-613.
2. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. New Engl J Med. 2013;368(19):1771-1780.
3. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850): 1309-1316.
4. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002;16(1):34-45.
5. Webert K, Cook RJ, Sigouin CS, Rebulla P, Hedde NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006;91(11): 1530-1537.
6. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med. 1997;337(26):1870-1875.
7. Estcourt LJ, Heddle N, Kaufman R, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013;53 (7):1531-1543.
8. Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Hedde NM. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion. 2012;52(11):2466-2474.
9. Cook RJ, Heddle NM, Rebulla P, et al. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion. 2004;44(8):1135-1142.
10. Stanworth S, Estcourt LJ, Llewelyn C, et al. for the TOPPS study investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a sub-group analysis of a randomized trial. Transfusion. 2014;54 (10):2385-2393.
11. McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman & Hall/CRC; 1989.
12. Therneau TM, Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York: Springer; 2000.
13. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003;96(10):711-729.
14. Kim CX, Bailey KR, Klee GG, et al. Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS One 2010;5(2): e9065.
15. Eliasson M, Evrin PE, Lundblad D, Asplund K, Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen: a population study. Fibrinolysis 1993;7(5):316-323.
16. Trentzsch H, Nienaber U, Behnke M, Lefering R, Piltz S. Female sex protects from organ failure and sepsis after major trauma hemorrhage. Injury. 2014;45 (Suppl 3):S20-28.
17. BCSH. British Committee for Standards in Haematology: guidelines for the use of platelet transfusions. Br J Haematol. 2003;122(1):10-23.
18. BCSH. British Committee for Standards in Haematology: transfusion guidelines for neonates and older children. Br J Haematol. 2004;124(4):433-453.
19. Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111(10): 4958-4964.
20. Ho-Tin-Noé B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost. 2011;9 (Suppl 1):56-65.
21. Estcourt LJ, Birchall J, Lowe D, Grant- Casey J, Rowley M, Murphy MF. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 2012;103(4):284-293.
22. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41(8): 977-983.
23. Valeri CR, Khuri S, Ragno G. Role of the Hct in the treatment of thrombocytopenic patients. Transfusion. 2003;43(12):1761-1762.